Antibody Engineering & Therapeutics
December 11-15, 2017
Manchester Grand Hyatt
San Diego, CA

THE LARGEST MEETING BRINGING YOU THE LATEST ANTIBODY SCIENCE, TECHNOLOGIES AND PARTNERS NEEDED TO ACCELERATE NEXT GENERATION ANTIBODIES TOWARDS COMMERCIAL SUCCESS

The Most Innovative Science Presented by Leading Industry and Academic Experts
The Largest Exhibition Devoted to Antibody Engineering
The Leading Forum to Partner with Global Antibody Innovators and Suppliers

Keynotes Speakers Share Strategies to Accelerate Your Antibody Molecules

DECIPHERING THE HUMAN IMMUNOME
James E. Crowe, Jr., M.D.,
Director, Vanderbilt Vaccine Center,
Vanderbilt University Medical Center

PARACRINE DELIVERY
Andreas Plückthun, Ph.D.,
Professor and Director,
Department of Biochemistry,
University of Zürich, Switzerland

BIOLOGIC DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER WITH IgG FUSION PROTEINS
William M. Pardridge, M.D.,
Distinguished Professor Emeritus, UCLA and Founder and Chief Scientific Officer, ArmaGen

OCRELIZUMAB IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
Peter Chin, M.D.
Group Medical Director, Neuroscience,
SPECTRUM Medical Unit, US Medical Affairs,
Genentech

Register by June 30 and Save Up to $600 www.antibodyeng.com
PRE-CONFERENCE TRAINING COURSE

Monday, December 11, 2017, 9:00am-5:00pm

Introduction to Antibody Engineering
Instructor: David Bramhill, Ph.D., Bramhill Consulting, LLC and Research Corporation Technologies

*Additional registration fee applies. See the pricing tier on page 8 or visit the website for more details

PRE-CONFERENCE WORKSHOPS

Monday, December 11, 2017, 1:00pm-5:00pm

Workshop A: Selecting Antibodies against Cell-Surface Targets
Workshop Moderator: Andrew Bradbury, M.D., Ph.D., Research Scientist and Group Leader, Los Alamos National Laboratories

Workshop B: Developability of Antibodies
Workshop Moderator: Mark Chiu, Associate Director of Development, Janssen R&D

*Additional registration fee applies. See the pricing tier on page 8 or visit the website for more details

MAIN CONFERENCE

Tuesday-Friday, December 12-15, 2017

ENGINEERING AND APPLICATION OF THERAPEUTIC ANTIBODIES FOR NEURODEGENERATIVE DISEASES

Session Co-Chairs:
Cynthia A. Lemere, Ph.D., Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School
Anne Messer, Ph.D., Professor of Biomedical Sciences, University at Albany and Principal Investigator, Neural Stem Cell Institute, Regenerative Research Foundation
James S. Huston, Ph.D., Chairman, The Antibody Society; Managing Member, Huston BioConsulting, LLC

Towards Development of Antibody Therapy for C9orf72 ALS/FTD
Laura P.W. Ranum, Ph.D., Director, Center for NeuroGenetics, Kitzman Family Professor of Molecular Genetics and Microbiology, College of Medicine, University of Florida

Antibody Therapy for Alzheimer’s Disease – Key Challenges
Christoph Hock, M.D., Professor and Director, Institute for Regenerative Medicine (IREM), University of Zurich and Co-Founder, Neurimmune, Switzerland

Altering APP Processing with a Proteolytic Diabody
Michael Sierks, Ph.D., Professor, Chemical Engineering, Arizona State University

Tau Immunotherapy
Peter Davies, Feinstein Institute for Medical Research, North Shore/LIJ Health System

PD Immunotherapy – A-Syn
Eliezer Masliah, M.D., Director, Division of Neurosciences, National Institutes of Aging, NIH

BIOLOGICAL IMPACT OF FC RECEPTOR ENGAGEMENT

Session Co-Chairs:
Trudi Veldman Ph.D., Senior Director Biologics, AbbVie Bioresearch Center Chung-Ming Hsieh, Executive Director, Biologics Discovery Boston, Merck Research Laboratories

SKY59: Novel Recycling Antibody against C5 with Improved Pharmacokinetics for the Treatment of Complement-mediated Diseases
Kenta Haraya, Ph.D., Scientist, Research Division, Biologics Discovery, Chugai Pharmaceutical Co Ltd., Japan

Novel Effector Function Attenuating Mutations That Maintain Antibody Stability and Reduce Toxicity
James A. Ernst, Ph.D., Senior Scientist & Group Leader, Department of Protein Sciences, Genentech

Selective FcγR Engagement by Agonistic Anti-CD40 Abs
Rony Dahan, Ph.D., Principal Investigator, Department of Immunology, Weizmann Institute of Science, Israel

Antibody Optimization for Treg Depletion in Cancer Therapy
Frederick Arce Vargas, M.D. Ph.D., Research Associate, University College London Cancer Institute, United Kingdom

Potent Antitumor Activity of IL2-Fc Requires Fc-mediated Depletion of Tregs
Daniel Christ, Ph.D., Associate Professor and Head Antibody Therapeutics, Director Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research

IMMUNO-ONCOLOGY: CHECKPOINTS

Session Chair:
James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

SIMPLE Antibody™ Platform Generates Unique Species Cross-reactive Antibodies against Immune Checkpoints
Erik Hofman, Ph.D., Senior Scientist, Research Department, Argenx, Belgium

A Novel Cytokine Receptor Agonistic Antibody by Design
Cheng-I Wang, Ph.D., Senior Principal Investigator, Singapore Immunology Network, Biomedical Sciences Institutes, ASTAR, Singapore

Cow Ultralong CDR3 Antibodies Targeting Exhausted T-cells
Vaughn Smider M.D., Ph.D., Associate Professor, Molecular Medicine, The Scripps Research Institute

Immuno-oncology and Prostate Cancer
Xin Lu, Professor M.D., University of Notre Dame

Boosting Cancer Immunotherapy with Combined Immunomodulatory Drugs
Mickey Hu, Ph.D., Scientist, Panorama Institute of Molecular Medicine

Register by June 30 and Save Up to $600 at www.antibodyeng.com
ROLE OF POST-TRANSLATIONAL MODIFICATION IN ANTIBODY FUNCTION

Session Co-Chairs:
Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute
Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, The Netherlands

Integrative Mass Spectrometric Structural Analysis of Glycoprotein Therapeutics and Its Usage to Evaluate and Score Biosimilarity
Albert J. R. Heck, Ph.D., Professor and Science Faculty, Utrecht University, The Netherlands

Post-translational Modification of Antibodies in Rheumatoid Arthritis
Leenert A. Trouw Ph.D., Assistant, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Regulation of Autoantibody Activity by the IL-23–TH17 Axis and Its Impact on Autoimmune Disease
Gerhard Krönke, M.D., Professor of Translational Immunology, Department of Internal Medicine 3, Institute of Rheumatology and Immunology, University of Erlangen-Nuremberg Germany

Fc Fucosylation and Sialylation and Antibody Effector Function
Jeffrey Ravetch, Ph.D., Professor, Rockefeller University

Sulfation of Broadly Neutralizing HIV Antibodies
Raiees Andrabi, Research Associate, The Burton Lab, The Scripps Research Institute

ANTIBODY BASED INNOVATIONS IN THE TUMOR MICROENVIRONMENT

Session Co-Chairs:
Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, United Kingdom
Janine Schuurman, Ph.D., Vice President, Research, Genmab, The Netherlands

Protia – Bispecific T-Cell Engagers Designed for Local Activation in the Tumor Environment
Volker Schellenberger, Ph.D., CEO and President, Amunix

Immuno-Viral Therapy for Solid Tumors
Maria Navarro, M.D., Project & Operations Manager, Icell Kealex Therapeutics

Costimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART® and TRIDENT™ Molecules
Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics

Harnessing Fc Gamma Receptor Biology to Optimize Antibodies Targeting TNFR Superfamily Members
Nick Wilson, Ph.D., Executive Director of Immuno-modulatory Drug Discovery, Agenus

mRNA Vaccination and Combination Therapy with Immunomodulating Antibodies
Sebastian Kreiter, Head, Tron/BioNTech, Germany

An Update on the Darzalex Story
Kate Sasser, Ph.D., Vice President, Head of Oncology Translational Research, Janssen

OVERCOMING DELIVERY CHALLENGES INCLUDING BRAIN AND INTRACELLULAR TARGETS

Session Co-Chairs:
Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.
Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, Switzerland

Bacterial Secretion Systems
Thomas Marlovits, Professor, Institute of Molecular Pathology, Austria

Nanobodies as Inhaled Biotherapeutics for Lung Diseases, with ALX-0171 (anti-RSV) as a Case Study
Antonin De Fourgerolles, Ph.D., Chief Scientific Officer, Ablynx, Belgium

Bispecific Antibodies Targeting Transferrin Receptor or CD98 to Facilitate Delivery across the Blood Brain Barrier
Jasi Atwal, Scientist, Genentech

Artificial immunotoxins
Ernst Wagner, Ph.D., Chair, Pharmaceutical Biotechnology, Center for System-based Drug Research, Center for Nanoscience, Ludwig Maximilians University, Germany

ANTIBODY-DRUG CONJUGATES & FUSION PROTEINS

Session Chair:
Gregory Adams, Ph.D., Chief Scientific Officer, Eleven Biotherapeutics

Redox Selenium ADCs Improve Cancer Cell Monoclonal Antibody Cytotoxicity
Julian Spallholz, Ph.D., Professor, Nutritional Sciences, Texas Tech University

Antibody-drug Conjugates for Treating Steroid-resistant Malignancies and Autoimmune Diseases
Masahiro Yasunaga, M.D., Ph.D., Unit Leader, Developmental Therapeutics, National Cancer Center, Japan

Targeting Tumors and Their Vasculature with Antibody-drug Conjugates
Dimiter Dimitrov, Ph.D., Senior Investigator, CCR, Cancer and Inflammation Program, NCI-Frederick, NIH

Novel Calicheamicin Antibody-Drug Conjugates
Julia Gavrilyuk, Ph.D., Principal Scientist, Discovery Chemistry, Abbvie Stemcentrx

NOVEL ANTIBODY DISPLAY, SELECTION AND SCREENING TECHNOLOGIES

Session Chair:
Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Using Next Generation Sequencing in Antibody Libraries
Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica

Engineering Developable Antibodies
Peter Tessier, Professor, Rensselaer Polytechnic Institute

Advances in Yeast Display Selections for Membrane Targets
Benjamin Hackel, Ph.D., Assistant Professor, Chemical Engineering and Materials Science, University of Minnesota

Quantitative Proteomics
Jim Wells, Professor, UCSF

Programming Antibodies and Antigens using Deep Sequencing-Enabled Protein Engineering
Tim Whitehead, Ph.D., Associate Professor, Chemical Engineering and Materials Science, Michigan State University

Functional Interrogation and Mining of Natively Paired Heavy/Light Human Antibody Repertoires
Department of Pharmaceutical Chemistry, The University of Kansas

Register by June 30 and Save Up to $600 at www.antibodyeng.com
ROLE OF THE T-CELL REPERTOIRE IN CANCER, INFECTIOUS DISEASES AND AUTOIMMUNITY

Session Chair:
Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, Canada

Genetic Variation in MHC Proteins is Associated with T-cell Receptor Expression Biases
Eilon Sharon, Ph.D., Postdoctoral Fellow, Howard Hughes Medical Institute, Stanford University

CD8 T-cell Repertoire Dynamics and Their Association with HCV Clearance
Naglaa H. Shoukry, Ph.D., Associate Professor, Department of Medicine, University of Montreal, Canada

CD39 and CD103 Identify Tumor-reactive CD8 T-cells in Human Solid Tumors
Thomas Duhen, Ph.D., Senior Research Scientist, AgonOx

ANTI-TUMOR ANTIGEN ANTIBODIES IN CANCER IMMUNOTHERAPY

Session Chair:
K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

Tumor Targeting Antibodies: Distinct Innate and Adaptive Immune Sensing
Yang-Xin Fu, M.D., Ph.D., Professor of Pathology, Mary Nell and Ralph B. Rogers Professorship in Immunology, UT Southwestern

Innate and Adaptive Integrin-targeted Combination Immunotherapy
Jennifer R. Cochran, Ph.D., Co-Founder and Director, Nodus Therapeutics

NK Cell Engagement with Bispecific Antibodies
Ann Cheung, Ph.D., Director of Biology, Dragonfly Therapeutics

Anti-chaperone Antibodies in Cancer Therapy
Amy S. Lee, Ph.D., Associate Director for Basic Research, USC Norris Comprehensive Norris Cancer Center and Professor of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California

NOVEL THERAPEUTIC INDICATIONS FOR ANTIBODIES

Session Chair:
James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

Antibody Approaches to T1D
William Ridgway, Professor, University of Cincinnati

Action of Bispecific Anti-FGFR1/βKlotho Antibody in Obese Mice and Humans
Junichiro Sonoda, Ph.D., Senior Scientist, Cancer Immunology, Genentech

Therapeutic Antibodies that Silence B Cells by Emulating Peripheral Immune Tolerance
John Cambier Ph.D., Distinguished Professor and Chair, Department of Immunology and Microbiology, University of Colorado SOM

NOVEL ENGINEERING STRATEGIES TO ENHANCE ANTIBODY FUNCTIONS

Session Chair:
Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.

From Format to Function - Transformative Antibody Therapeutics
Martin Steegmaier, Ph.D., Head of Discovery, Large Molecule Research, Roche pRED, Roche Innovation Center Munich, Germany

Anti-OX40 Agonist Antibodies
Gregory Lazar, Scientist, Genentech

Adapted Fc-glycan changes for enhanced ADCC and/or CDC
Gestur Vidarsson, Ph.D., Head of Immunoglobulin Research/PI, Experimental Immunohematology, Sanquin Research, The Netherlands

INNOVATING ANTIBODY THERAPEUTICS

Session Chair:
Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, The Netherlands.

Evolution of Antibodies of Different Germline Gene Origins Proceed through Different Paths
Mats Ohlin, Ph.D., Professor, Department of Immunotechnology & SciLifeLab, Lund University, Sweden

DNA-based Antibody Therapy via Antibody Gene Transfer
Kevin Hollevoet, Ph.D., Group Leader and Postdoc, Therapeutic and Diagnostic Antibodies, University of Leuven, 5

Structural Determinants for Modulating Antibody-Fc Receptor Interactions for Half-Life Enhancement and Effector Functions
Karthik Viswanathan, Ph.D., Director, Research, Visterra, Inc.

Register by June 30 and Save Up to $600 at www.antibodyeng.com
Academic/Government rates are extended to full-time employees of government, universities and university-affiliated hospitals only.

To register for only a training course or symposia, please contact Brian Schiff at brian.schiff@knect365.com or 646-895-7444.

Present a Poster to Showcase Your Company’s Latest Research
Highlight your company’s exciting research by presenting a scientific poster, which will be displayed in the exhibit & poster hall during the event. You must be a registered attendee to present a poster. Poster fee is $125 for industry attendees and free for academic/government attendees. The deadline to submit your poster is November 10, 2017.

REGISTER A GROUP OF 4+ AND SAVE UP TO $200/PERSON
Companies that register 4+ attendees are eligible to receive up to an additional $200 savings per person off the current registration rate. Register your group today at the lowest rate by contacting Brian Schiff at brian.schiff@knect365 or +1-646-895-7444.

Sponsorship/Exhibition Opportunities
Highlight your expertise directly to 800+ scientists and high level decision makers and influencers working across antibody engineering, antibody therapeutics and protein discovery and development by becoming an event sponsor or exhibitor. Contact Aimee Croke at aimee.croke@knect365.com or (857) 504-6697 for pricing and package details, or to see a sample attendee list from Antibody Engineering 2016. Reserve your spot early to ensure company placement in our printed brochure.

Venue Information:
Manchester Grand Hyatt San Diego
1 Market Place, San Diego, CA 92101
Phone: (888) 421-1442
Special Attendee Room Rate: $230/night + tax
Please call the hotel directly at the number above or book online and reference “Antibody Engineering” to receive the reduced room rate. Special hotel rates are good through November 6th or until room block is sold-out.

Register by June 30 and Save Up to $600 at www.antibodyeng.com